-transparent.png){kind=logo}
Dazoxiben, a thromboxane synthase inhibitor, inhibits arachidonic acid induced aggregation in platelet-rich plasma from some donors only ("responders"). We have studied the effect of dazoxiben in vitro on platelet aggregation and prostaglandin (PG) metabolism and the influence of the incubation period and of exogenously added serum albumin (SA). SA, which increases the production of anti-aggregatory PGD2 from cyclic endoperoxides, induced "non-responder" human platelets to respond. With rabbit platelets, however, that are insensitive to PGD2, exogenous SA failed to potentiate dazoxiben-induced inhibition. The ratio between PGD2 and TXB2 + PGE2 formed was crucial in determining the response of human platelets to dazoxiben: whenever this ratio was high, platelet aggregation was inhibited. SQ 22536, an adenylate cyclase inhibitor, and NO164, a PGD2 antagonist, reversed the inhibition by dazoxiben in human platelet-rich plasma, stressing the importance of a PGD2 mediated rise of cyclic AMP for the effectiveness of a thromboxane synthase inhibitor.
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
September 1985,
Thrombosis research,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
August 2003,
Biochemical pharmacology,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
August 1985,
Prostaglandins, leukotrienes, and medicine,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
August 1990,
Prostaglandins,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
January 1976,
Advances in prostaglandin and thromboxane research,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
March 2010,
Archives of pharmacal research,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
February 1973,
Prostaglandins,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
August 1980,
European journal of biochemistry,
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
April 1979,
Lancet (London, England),
P Gresele, and
H Deckmyn, and
E Huybrechts, and
J Vermylen
October 2001,
Canadian journal of physiology and pharmacology,
